ESMO FAMILY SITES
ESMO Metastases Virtual Meeting
On behalf of the Scientific Committee, it is our great pleasure to invite you to join the ESMO Virtual Meeting on Metastases. Join this unique online experience at the convenience of your own home!
The ESMO Virtual Meeting on Metastases will focus on the biology of this most lethal hallmark of cancer and the impact of tumor microenvironment on cancer metastases initiation and progression. Invited speakers will provide an international expertise on the basic science and its clinical translation to practice for lymph node, hematopoietic, brain, lung, liver and bone metastases. Lectures will cover traditional and new concepts in research of metastases, including ectopic homing, dormancy, early colonization and migration. The program will also cover the biological rationale for new therapeutic strategies, drugs in development, the use of biomarkers and therapy resistance. A special part of the meeting will be dedicated to the pathophysiology of bone metastases, their prevention, functional imaging, multidisciplinary management and clinical application and integration of bone-targeted treatments.
The meeting will be available as a Webcast from February 2012. ESMO members will have free access on OncologyPRO, and non-members will have the opportunity to register online
"Much progress has been recently accomplished in the understanding, the monitoring and the treatment with bone-targeted drugs of tumor bone disease. Bone can be the source of secondary metastases and inhibitors of bone resorption can decrease the recurrence rate in the metastatic setting. Prevention trials using bone targeted treatments are now ongoing. Attending this virtual meeting will allow you to better understand the considerable progress made recently in the field of "bone and cancer" and to optimise the care of your patients."
Dr. Jean-Jacques Body
"Bone targeted treatments have transformed the care of patients with bone metastases and have an increasing role in metastasis prevention and maintenance of a healthy skeleton. Attend this virtual meeting to hear about the latest information on disease mechanisms, pharmacology and efficacy of bone targeted agents and how to optimise the multidisciplinary management of metastatic bone disease."
Dr. Robert Coleman
"Metastasis has only recently gained specific scientific attention, while the traditional focus on the primary tumor, regarding its role as surrogate marker for the biology of metastasis and for therapeutic decisions, is still predominant. This can be easily observed in several experimental models as well as in current attempts to select therapy targets for systemic cancer after mutational or molecular profiling of primary tumors. The virtual meeting will therefore explore mechanisms of lymphatic and hematogenous spread as well as mechanisms involved in organ-site specific and iatrogenic selection and adaptation of metastatic tumor cells."
Dr. Christoph Klein
BACK TO TOP
PRINT THIS PAGE